Jazz Pharmaceuticals Public Limited Company filed a Form 8-K with the SEC on September 15, 2026, disclosing the completion of its acquisition of Actio Biosciences, Inc.

Key Highlights

  • Acquisition completed: Jazz Pharmaceuticals announced the completion of its acquisition of Actio Biosciences, Inc., a Delaware corporation.
  • Wholly-owned subsidiary: Following the acquisition, Actio Biosciences became a wholly-owned subsidiary of Jazz Pharmaceuticals.
  • Event date: The acquisition completion was announced on September 15, 2026, via a press release.
  • Disclosure type: The information was furnished under Regulation FD and is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.
  • Signed by: Philip L. Johnson, Executive Vice President and Chief Financial Officer, signed the filing on behalf of the registrant.

Jazz Pharmaceuticals Closes Actio Biosciences Deal, Adding Wholly-Owned Subsidiary

According to the filing, Jazz Pharmaceuticals Public Limited Company, an Irish public limited company listed on NASDAQ:JAZZ, issued a press release on September 15, 2026, confirming that it had completed the acquisition of Actio Biosciences, Inc. The filing was submitted under Item 7.01 (Regulation FD Disclosure) of Form 8-K, with the press release attached as Exhibit 99.1.

The filing states that, following the closing of the transaction, Actio Biosciences, Inc. became a wholly-owned subsidiary of Jazz Pharmaceuticals. No financial terms of the acquisition, such as purchase price or consideration paid, were disclosed within the body of the 8-K filing itself. The press release attached as Exhibit 99.1 is described as incorporated by reference but its full contents were not reproduced in the filing text provided.

The registrant noted that the information furnished under Item 7.01, including the attached press release, "shall not be deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section," and shall not be deemed incorporated by reference into other regulatory filings unless expressly set forth by specific reference. The filing was signed by Philip L. Johnson, Executive Vice President and Chief Financial Officer.

What Was Disclosed

Jazz Pharmaceuticals filed an 8-K on September 15, 2026, reporting the completed acquisition of Actio Biosciences, Inc., which became a wholly-owned subsidiary. The disclosure was furnished under Regulation FD and is not deemed filed under Section 18 of the Exchange Act.